Antibiotics need a special place in the drug pricing debate
08 January 2020
Melinta Therapeutics, one of the few companies to recently bring a new antibiotic to market, filed for bankruptcy at the end of December. This news comes less than a year after another antibiotic developer, Achaogen, did the same thing.
More than 90% of antibiotics in the pipeline today are being developed by small companies like these, not by the pharmaceutical giants that once dominated the field. And with antibiotic prices low and profit margins narrow, many small companies just can’t stay afloat.
That’s a big problem — a problem that puts us all at risk.
Further reading: Stat News
Author(s): Allan Coukell
Smart Innovations
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!